-
Mashup Score: 0Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut - 6 month(s) ago
Key Points. Time-limited triple therapy leads to high rates of undetectable minimal residual disease and sustained remissions in high-risk CLL.Adverse events oc
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial - 7 month(s) ago
Key Points. Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.AE burden score all
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Detailed safety profile of #Acalabrutinib vs #Ibrutinib in previously treated #CLL in the #ELEVATE-RR trial 👉https://t.co/Y7bNzp0oC7 @MDedgeHemOnc #RiskBenefit https://t.co/2gnp1gfK4v
-
-
Mashup Score: 0article - 7 month(s) ago
NewsOncology Times45(S10):p 3, May 20, 2023. | DOI: 10.1097/01.COT.0000936928.77325.9bChronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaAbout one-third of patients with advanced chronic lymphocytic leukemia (CLL) treated with the targeted drug ibrutinib do not carry two mutated genes commonly associated with relapse, according to an international study published in Blood Advances (2023;…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
About one-third of patients with advanced #ChronicLymphocyticLeukemia (CLL) treated with the targeted drug #ibrutinib do not carry two mutated genes commonly associated with #relapse, according to a study published in Blood Advances. https://t.co/HBLxoK0bCz #ThisIsBloodCancer https://t.co/u8e0YB3kJ1
-
-
Mashup Score: 0Fixed-Duration, Triple-Combination Therapy Shows Efficacy for Patients With High-Risk CLL | ASH Clinical News | American Society of Hematology - 7 month(s) ago
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. The triple combination of obinutuzumab, ibrutinib, and venetoclax has shown a relatively high response rate among previously untreated patients with high-risk chronic lymphocytic leukemia (CLL), according to study results published in Blood. The limited-duration triple combination therapy achieved a complete response of 58.5% in the phase II CLL2-GIVe trial of 41 patients with high-risk CLL. Most adverse events
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In previously untreated patients with high-risk chronic lymphocytic #leukemia #CLL, a limited-duration combo therapy of #obinutuzumab, #ibrutinib, and #venetoclax achieved a complete response of 58.5% in the phase II CLL2-GIVe trial. https://t.co/jQRGGBe5v6
-
-
Mashup Score: 0article - 7 month(s) ago
NewsOncology Times45(S10):p 3, May 20, 2023. | DOI: 10.1097/01.COT.0000936928.77325.9bChronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaAbout one-third of patients with advanced chronic lymphocytic leukemia (CLL) treated with the targeted drug ibrutinib do not carry two mutated genes commonly associated with relapse, according to an international study published in Blood Advances (2023;…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ibrutinib, which targets BTK, has been highly effective in treating #CLL patients. Despite its success, about 6% of CLL patients develop resistance to or #relapse within 6-12 months of starting #ibrutinib, and an additional 14% do so within 2 years. https://t.co/h7hqZWxzgn https://t.co/OxVFtHSG68
-
-
Mashup Score: 0
At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 @ASCO annual meeting, Kerry Anne Rogers, MD, provided insights into real-world dosing #ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia #CLL. Learn more here:https://t.co/HDDl8KgOdI https://t.co/F41KBZ5OZZ
-
-
Mashup Score: 0Nivolumab Plus BTK Inhibitor Ibrutinib Demonstrates Activity, Safety Among Patients With DLBCL Richter Transformation - 8 month(s) ago
According to a phase 2 trial, the combination of nivolumab and BTK inhibitor ibrutinib is an active and safe regimen among patients with diffuse large B-cell lymphoma Richter transformation.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to Nitin Jain, MD, and coauthors, "Combined #nivolumab and #ibrutinib is an active and safe regimen for patients with #DLBCL RT.” Read more: https://t.co/VaYkRj8uzV #BTK @NitinJainMD @MDAndersonNews https://t.co/rDC1JpATqt
-
-
Mashup Score: 0What were the results of the phase 3 gaia CLL13 trial [2023]? - 9 month(s) ago
Barbara Eichhorst, MD Professor of Medicine at UNIVERSITÄTSKLINIKUM KÖLN, is the author of this OncologyTube.com video. Timestamps: 0:09 Can you tell us about the CELL Trial and it´s design and any significant data. 3:04 How many patients were enrolled in the study and what were the characteristics o…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🧪 Phase 3 trial aims to replace standard chemo with targeted combos (#Venetoclax #Ibrutinib) + anti-CD20 antibodies in mutation-lacking #CLL patients. Join Barbara Eichhorst, MD @UKKoeln in this [video] https://t.co/YmMPLFvviB. #Leukemia https://t.co/BqmyLy7vNg
-
-
Mashup Score: 3Bleeding risk with concurrent use of anticoagulants and ibrutinib: A population‐based nested case‐control study - 9 month(s) ago
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Source: onlinelibrary.wiley.comCategories: Hematologists1, Latest HeadlinesTweet-
🩸Bleeding risk with concurrent use of #anticoagulants and #ibrutinib: A population-based nested case-control study 🇫🇷 https://t.co/ZTwv8dXRms Poke @DrAlexisTalbot #LLC #BTK
-
-
Mashup Score: 0Tolerability of Zilovertamab and Ibrutinib in Phase 1/2 Trial of MCL - 11 month(s) ago
Hun Ju Lee, MD, discusses the early results of the dose finding and safety study of zilovertamab plus ibrutinib for patients with mantle cell lymphoma as well as chronic lymphocytic leukemia and marginal zone lymphoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video with Hun Ju Lee, MD, a study of #zilovertamab + #ibrutinib for patients with #MCL, #CLL, and #MZL is discussed. #lymsm | @MDAndersonNews https://t.co/PXWygCo0sC
-
Final analysis of the #CLL2-GIVe trial: #obinutuzumab, #ibrutinib, and #venetoclax for untreated CLL with del(17p)/TP53mut 👉https://t.co/xKxTqFowPs @Blood @UniklinikUlm🇩🇪| #Multicenter https://t.co/nKHcjFeGkg